WHO Classification of Genetic Tumour Syndromes, WHO/IARC,
Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma, EADV,
Drug Hypersensitivity Skin Testing: Methods and Non-Irritative Concentrations, EAACI,
Levodopa and Melanoma in Parkinson's Disease, MDS,
The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus, BSR (UKKA-endorsed),
Bacterial Skin and Soft Tissue Infections in Children, CPS,
Quality-of-Life Measurement in Hidradenitis Suppurativa: 2026 Update, EADV,
Invasive Cutaneous Squamous Cell Carcinoma: Diagnosis and Prevention, EADO/EDF/ESTRO/UEMS-DV/EORTC,
Treatment of Invasive Cutaneous Squamous Cell Carcinoma, EADO/EDF/ESTRO/UEMS-DV/EORTC,
Topical Corticosteroids for Acute Radiation Dermatitis, MASCC,
Management of Atopic Dermatitis in Children and Adolescents, AAD,
Uveal Melanoma, ESMO/EURACAN,
Management of Classic Lichen Planopilaris, EADV,
Treatment of Acne: 2026 EuroGuiDerm Update, EuroGuiDerm,
Management of Nodular Prurigo, BAD,
Autoimmune Blistering Diseases in Children and Adolescents, EADV,
Non-Biological and RNA-Based Therapies for Chronic Inflammatory Diseases, EAACI,
Definition, Classification, Diagnosis and Management of Urticaria, GA²LEN/EuroGuiDerm/APAAACI/AAD/BSACI/GAAACI,
Treatment of Systemic Lupus Erythematosus, ACR,
Difficult-to-Manage and Treatment-Refractory Psoriatic Arthritis, EULAR,
Management of Behçet’s Disease — 2025 Living Update, BAD/BSR,
Management of Psoriatic Arthritis, APLAR,
Treatment of Systemic Sclerosis, EULAR,
Management of Systemic Sclerosis, BSR,
Management of Behçet’s Disease — 2024 Living Guideline, BAD/BSR,
Pharmacological Management of Psoriatic Arthritis, EULAR,
